Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Silver ETF (AGQ) vs BridgeBio Pharma Inc (BBIO) Price & Performance

ProShares Ultra Silver ETFTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Silver ETF vs BridgeBio Pharma Inc — how do they compare? ProShares Ultra Silver ETF trades at $82.68, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.

AGQBBIO
Sector
Leveraged / InverseHealth
52-Week High
$400.47$90.17
52-Week Low
$49.73$47.29
Market Cap
$16.61B
Enterprise Value
$18.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Silver ETF

ProShares Ultra Silver (AGQ) is trading at $76.86, up 5.97% on strong silver price momentum. The technical picture shows bullish moving averages with RSI indicating potential overbought conditions near resistance at $78. Recent news highlights AGQ's 9.39% surge as silver rallied 4-5%, though structural decay concerns persist for this 2x leveraged ETF.

The outlook remains volatile with silver price movements driving performance. Investment opportunity exists for bullish silver investors seeking amplified exposure, but structural decay and beta slippage present significant risks. AGQ consistently underperforms unlevered silver ETFs over time, making it suitable only for short-term tactical positions.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Silver ETF

AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.

Read more on AGQ

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO